PTO/SB/06b (08-08)

Approved for use through 08/31/2008. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Hodor the Denominal Regulation Act of 1996, no persons are required to rec-

Substitute for form 14498/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/587,960	
				Filing Date	March 22, 2007	
				First Named Inventor	Eric Nadeau	
				Art Unit	1651	
				Examiner Name	Davis, Ruth A	
Sheet	1	of	1	Attorney Docket Number	2003390-0033	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²				
		Armoid S., Gasaner B., Giger T. and Zwehlen R. Banning astimicrobial growth promoters in fastetuffs does not result in increased therapeutic use of artibiolics in medicated feed in pig farming. Pharmacoepidemiology and Drug Safety 2004; 13: 323-331.					
		Wagener HC, Asrestrup FM, Bogo Jamean L, Hammerum AM and Bager F. Use of entimicrobial growth promoters in tode snimels and Entancoccus fascium resisfance to therepautic enteriorobial drugs in Europe. Emerging Infectious Diseases 1699, 8 (3): 329-335.					
	;	Somwarz S, Kahrenberg C and Waleh TR. Use of antimicrobial agents in veterthally medicine and food animal production. Informational Journal of Antimicrobial Agents 2001; 17: 431-437.					
		Barnardasu M, Verroux JP and Gusguen M. Safety and afficacy of problotic sadobadal in promoting growth in post-weening Swiss mice. International Journal of Food Microbiology 2002; 77(1-2): 19-27.					

Examiner Signature	/Ruth A. Davis/ (04/29/2010)	Date Considered	04/29/2010

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no

EXPANSIVE INTERPRETATION OF THE PROPERTY OF THE INTERPRETATION OF oghthering, processing and submitting to completed applications form to the USPTO. Three will vary depending upon the familiarial case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent on Chief Information Officer, U.S. Patient and Trademork Officer, U.S. Patient and Assambles, V.S. 2314-4440, D. NOTE SEND PEED OR COMPLETED FORMST OTHER ADDRESS, SERIOR TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.